As indicated earlier, the scientific implications of EVA extend well beyond the creation of the largest, systematically developed quality controlled and validated virus collection in the world. For example, a wide variety of research infrastructures, including medicine, industry, academia, health agencies, other government agencies and other end-users could potentially benefit their research and development programmes by exploiting the EVA collection and its associated reagents, which, under contract, could be custom-designed (including the viruses). Thus, they could have the capacity to investigate and develop novel, and in some cases, unanticipated areas of research, hitherto inaccessible to their fields of interest, with a more coordinated approach. Additionally, by exploiting the knowledge and experience of the individual partners in EVA, they will gain access to Europe’s finest scientists in fundamental and applied research, public health, veterinary medicine, and specific training and education programmes